Skip to main content

dosing

Colette S
Actual Nurtec ODT Patient

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed,
number one in new prescriptions, and more neurologists selected as brand of choice

One medication in a 75 mg dose puts the power to treat or prevent in your patient's hands1

TREATING MIGRAINE ATTACKS
Once daily PRN. Take one 75 mg ODT, as needed, for acute treatment of migraine.1

Patients with a history of 9 to 14 monthly moderate or severe migraine attacks treated with Nurtec 75 mg as needed up to once per day (median usage 8 tablets/month).2

Lazy

Up to 18 doses per month1

PREVENTING THE NEXT ONE
Take one 75 mg ODT every other day for preventive treatment of episodic migraine.1

90% of patients in the clinical study adhered to the every other day dosing regimen.3

A non-CGRP acute treatment can be used on days when Nurtec ODT is taken, if needed.3

Nurtec ODT is supplied in a carton containing an 8-pack1

I was trying to manage my workload when I got a migraine. I put the Nurtec ODT tablet under my tongue and hoped it would work. Probably an hour later, I realized my migraine pain was relieved.

Chasity H

Actual Nurtec ODT patient 
Individual results may vary.

I love that I can take one blister pack with me just in case I need it.

Jenaleigh D

Actual Nurtec ODT patient 
Individual results may vary.

one quick-dissolving dose. anytime. anywhere.1

The only CGRP receptor antagonist available as an ODT.1,4

CGRP: calcitonin gene-related peptide

No titration needed1

Can be taken up to once daily as needed. No water necessary.1,*

Can be co‑administered with oral contraceptives and antidepressants.1,5,6

Shown to both treat and prevent attacks, including in patients already on a preventive treatment1

Not contraindicated in patients with stable cardiovascular disease or risk factors.1,7

*Up to 18 doses of Nurtec ODT can be taken per month.1

Convenience of one rapidly disintegrating dose1,4

How to Take

ready

Instruct patients to only remove Nurtec ODT from the blister pack immediately before use1

No titration needed1

set

Patients can place Nurtec ODT on or under their tongue and it dissolves within seconds—no water needed1,8

go

Patient can carry on after taking a single tablet of 75 mg for either acute or preventive treatment1

Nurtec ODT has a Tmax of 1.5 hours1

Study designs

For the acute indication, Nurtec was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), with co‑primary endpoints at 2 h for Nurtec ODT vs placebo: pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptoms (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%; P=.001).1

For the preventive indication, rimegepant 75 mg was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 695 patients (rimegepant 75 mg, n=348; placebo, n=347) with the primary endpoint being change from baseline in the mean number of monthly migraine days during weeks 9‑12 (-4.3 vs -3.5, P=.01).1

A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).1,9

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 4. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 5. Hutchinson S, Schim J, Lipton RB, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 6. Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 7. Data on File. RIM130. Biohaven Pharmaceuticals Inc. 8. Abay FB, Ugurlu T. Orally Disintegrating Tablets: A Short Review. J Pharm Drug Devel. 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303. 9. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; 2020.